Clinical

Dataset Information

0

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients


ABSTRACT: Colorectal cancer may be caused by a build-up of genetic defects, or damaged genes within the body’s cells. When genes are damaged, the body may be unable to produce a group of proteins, called cytokines, used by the immune system to fight cancer and some infections. The investigational gene transfer agent EGEN-001 contains the human gene for the cytokine interleukin-12 (IL-12) in a special carrier system designed to enter the cells and help the body to produce cytokines.Therefore Therefore, the purpose of the EGEN-001 therapy is to attempt to enhance the body’s natural ability to recognize and fight cancer cells.

DISEASE(S): Peritoneal Neoplasms,Carcinoma,Colorectal Cancer

PROVIDER: 2102659 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2170258 | ecrin-mdr-crc
2020-04-28 | GSE149417 | GEO
2022-06-14 | MODEL1909260004 | BioModels
2023-11-27 | MODEL1909260005 | BioModels
2023-11-27 | MODEL1909260006 | BioModels
| 2009653 | ecrin-mdr-crc
| 2761466 | ecrin-mdr-crc
| 2396238 | ecrin-mdr-crc
2023-11-27 | MODEL1909260003 | BioModels
2018-06-01 | GSE107209 | GEO